# Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

> **NCT03012061** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 425 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** UMEC
- **DRUG:** Fluticasone Furoate
- **DRUG:** Albuterol/salbutamol

## Key facts

- **NCT ID:** NCT03012061
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-25
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-05-30
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03012061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03012061, "Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03012061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*